Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430395 | 0.82 | LHCGR (0.51) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL4423867 | 0.78 | LHCGR (0.48) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL4428948 | 0.77 | LHCGR (0.52) | LHCGRTSHRLMNAKDM4EADORA2A | |
| SCHEMBL27502613 | 0.76 | LHCGR (0.63) | LHCGRTSHRKMT2ACYP1A2CYP3A4 | |
| SCHEMBL4423898 | 0.75 | LHCGR (0.55) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL7143226 | 0.72 | LHCGR (0.51) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL4423876 | 0.71 | LHCGR (0.56) | LHCGRTSHRADORA2A | |
| SCHEMBL4432167 | 0.71 | LHCGR (0.54) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL4425051 | 0.71 | KDM4E (0.55) | LHCGRTSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL4418728 | 0.71 | LHCGR (0.57) | LHCGRTSHRKDM4EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1886999-A2 | Bicyclic heteroaromatic compound | N.V. Organon (NL) | 2008-02-13 | — | — | EP | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
| EP-1322651-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024703-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | AKZO NOBEL N.V. (NL) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 13/4885TSHR 1000/4885LMNA 1352/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | LHCGR 10/4885TSHR 517/4885LMNA 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.